Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
In part due to research by two University of Michigan researchers, a form of leukemia can be treated more easily through an FDA-approved drug.
News Medical on MSN
Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias
Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...
A recent study shows a regimen of low-dose homoharringtonine, cytarabine, and G-CSF (HAG) is an effective and promising treatment for pediatric patients with AML.
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
Lynozyfic (linvoseltamab), a B-cell maturation antigen and CD3 bispecific antibody, showed a high overall response rate and a ...
Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback